Literature DB >> 31376264

Distinct clinical characteristics of anti-Ro/SSA-negative primary Sjögren's syndrome: data from a nationwide cohort for Sjögren's syndrome in Korea.

Youngjae Park1, Jennifer Lee1, Jung Hee Koh2, Yoon-Kyoung Sung3, Shin-Seok Lee4, Jung Yoon Choe5, Seung-Cheol Shim6, Ji-Min Kim7, Sung Ryul Kwon8, Hyun-Ok Kim9, So-Hyang Chung10, Sung-Hwan Park11, Seung-Ki Kwok12.   

Abstract

OBJECTIVES: To investigate clinical characteristics of patients with primary Sjögren's syndrome (SS) who were negative for anti-Ro/SSA antibody but positive for minor salivary gland biopsy (MSGB) compared to patients who presented positivity for anti-Ro/SSA antibody.
METHODS: The data of 355 patients from the Korean Initiative of primary Sjögren's Syndrome (KISS), a nationwide prospective cohort for primary SS in Korea, were analysed. All patients fulfilled the 2016 American College of Rheumatology/European League Against Rheumatism (EULAR) classification criteria. Of these patients, 326 were positive for anti-Ro/SSA antibody and 29 were antibody-negative, although they had positive findings in MSGB. Various clinical features including all kinds of tests for evaluating secretory function, disease-related clinical indices and serological values available in the cohort were compared between the two groups.
RESULTS: The anti-Ro/SSA-negative group showed less rheumatoid factor positivity (p<0.001), leucopenia (p=0.003), hyper-gammaglobulinaemia (p<0.001), lower serum β2-microglobulin level (p=0.034), more anti-centromere antibody positivity (p<0.001), higher score in dryness domain of EULAR SS patient-reported index (p=0.048) and more positivity for peripheral nervous system domain in EULAR SS disease activity index and loss of teeth in SS disease damage index (p=0.021 and 0.041, respectively) than patients who were positive for anti-Ro/ SSA antibody.
CONCLUSIONS: Primary SS patients who are negative for anti-Ro/SSA antibody have different clinical characteristics compared to patients who are positive for such antibody in Korea. Therefore, clinicians should consider MSGB in patients with suspicious symptoms who are anti-Ro/SSA-negative.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31376264

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  4 in total

1.  Clinical and serological characteristics of seronegative primary Sjögren's syndrome: a comparative study.

Authors:  Veli Yazisiz; Bengisu Aslan; Funda Erbasan; İsmail Uçar; Tahir Saygin Öğüt; Mustafa Ender Terzioğlu
Journal:  Clin Rheumatol       Date:  2020-06-05       Impact factor: 2.980

2.  Peripheral Nervous System Involvement in Sjögren's Syndrome: Analysis of a Cohort From the Italian Research Group on Sjögren's Syndrome.

Authors:  Giacomo Cafaro; Carlo Perricone; Francesco Carubbi; Chiara Baldini; Luca Quartuccio; Roberta Priori; Onorina Berardicurti; Francesco Ferro; Saviana Gandolfo; Angelica Gattamelata; Roberto Giacomelli; Salvatore De Vita; Roberto Gerli; Elena Bartoloni
Journal:  Front Immunol       Date:  2021-03-24       Impact factor: 7.561

3.  Stimulated whole salivary flow rate: The most appropriate technique for assessing salivary flow in Sjögren syndrome.

Authors:  C Alvariño; L Bagan; J Murillo-Cortes; J Calvo; J Bagan
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2021-05-01

4.  Unstimulated whole saliva flow for diagnosis of primary Sjögren's syndrome: time to revisit the threshold?

Authors:  Valentin Lacombe; Carole Lacout; Pierre Lozac'h; Alaa Ghali; Aline Gury; Christian Lavigne; Geoffrey Urbanski
Journal:  Arthritis Res Ther       Date:  2020-02-24       Impact factor: 5.156

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.